Stockscreener 앱 받기
17.44
16.73%
2.50
시간 외 거래:
17.94
0.50
+2.87%
Atara Biotherapeutics Inc 주식(ATRA)의 최신 뉴스
Is Atara Biotherapeutics Inc. stock safe for conservative investorsProfit Target & Low Risk High Reward Ideas - ulpravda.ru
Why Atara Biotherapeutics Inc. stock attracts global investorsEarnings Trend Report & Risk Controlled Swing Alerts - ulpravda.ru
Why Atara Biotherapeutics Inc. stock is a value investor pickWeekly Trading Summary & Low Risk High Win Rate Picks - ulpravda.ru
Atara Stock Plunges To 3-Month Low After FDA Blocks Blood Cancer Drug: Retail's Buying The Dip - MSN
Why Atara Biotherapeutics Inc. stock could be next big winnerQuarterly Market Summary & Daily Entry Point Trade Alerts - ulpravda.ru
Atara Biotherapeutics prices $16M public offering - MSN
Atara Biotherapeutics Stock (ATRA) Jumps as FDA Decision on Viral Therapy Nears - TipRanks
How Atara Biotherapeutics Inc. stock performs in interest rate cyclesMarket Volume Summary & Fast Moving Stock Trade Plans - ulpravda.ru
Atara revises tab-cel commercialization milestones with Pierre Fabre - MSN
What drives Atara Biotherapeutics Inc stock priceBearish Engulfing Patterns & Build Balanced Portfolio - earlytimes.in
(ATRA) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Atara Biotherapeutics IncEntered fourth amendment with Pierre FabreSEC filing - marketscreener.com
Weekly Analysts’ Ratings Changes for Atara Biotherapeutics (ATRA) - Defense World
How Atara Biotherapeutics Inc. stock performs in stagflationHead and Shoulders Patterns & Easy Tools to Analyze Your Investment Risk - bollywoodhelpline.com
Technical Reactions to ATRA Trends in Macro Strategies - Stock Traders Daily
Biotech Stocks Facing FDA Decision In January 2026 - RTTNews
Can Atara Biotherapeutics Inc. stock deliver consistent earnings growthShort Interest Overview & Superior Trading Portfolio - bollywoodhelpline.com
Atara Biotherapeutics (ATRA) Price Target Increased by 15.69% to 20.06 - Nasdaq
Aug Outlook: Is Atara Biotherapeutics Inc. stock a good choice for value investors2025 Volume Leaders & AI Powered Market Trend Analysis - Улправда
Hedge Fund Bets: Can Atara Biotherapeutics Inc. stock deliver consistent earnings growthInsider Buying & Accurate Buy Signal Alerts - Улправда
Atara Biotherapeutics Earnings Notes - Trefis
Atara Biotherapeutics (ATRA) Sees Price Target Increase by Canac - GuruFocus
Is Atara Biotherapeutics Inc. (AT20) stock worth holding before Fed meetingEarnings Beat & Reliable Breakout Forecasts - Улправда
Can Atara Biotherapeutics Inc. stock surprise with earnings upsideJuly 2025 Drop Watch & Low Risk High Reward Trade Ideas - DonanımHaber
Is Atara Biotherapeutics Inc. stock a good choice for value investorsJuly 2025 Retail & Real-Time Volume Analysis Alerts - Улправда
(ATRA) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Is Atara's Tab-Cel The Missing Piece In A Difficult-To-Treat Cancer? - RTTNews
Panic Selling: Why Atara Biotherapeutics Inc stock could be next big winner2025 Buyback Activity & Fast Momentum Stock Entry Tips - moha.gov.vn
Atara Biotherapeutics price target raised to $140 from $131 at Mizuho - MSN
With Atara Biotherapeutics Stock Surging, Have You Considered The Downside? - Trefis
Would You Still Hold Atara Biotherapeutics Stock If It Fell Another 30%? - Trefis
Can Atara Biotherapeutics Stock Recover If Markets Fall? - Trefis
How Atara Biotherapeutics Inc. stock performs during Fed tightening cyclesWeekly Investment Report & Weekly Watchlist of Top Performers - Newser
Can Atara Biotherapeutics Inc. (AT20) stock hit consensus price targetsJuly 2025 Closing Moves & Daily Profit Maximizing Trade Tips - Newser
Is Atara Biotherapeutics Inc. (AT20) stock trading at attractive multiplesJuly 2025 Catalysts & Scalable Portfolio Growth Ideas - Newser
Why Atara Biotherapeutics Inc. (AT20) stock gets analyst attentionPortfolio Gains Summary & Daily Growth Stock Investment Tips - Newser
Is Confidence Futuristic Energetech Limited a Top Alpha Generator for Growth PortfoliosMarket Correction Analysis & Free Real-Time Trading Signals - earlytimes.in
Can Atara Biotherapeutics Inc. stock maintain operating margins2025 Key Lessons & Reliable Breakout Forecasts - Newser
Atara Biotherapeutics (ATRA) Stock Analysis Report | Financials & Insights - Benzinga
Atara Biotherapeutics (NASDAQ:ATRA) Stock Price Passes Below 50 Day Moving AverageHere's Why - MarketBeat
Why Atara Biotherapeutics Inc. (AT20) stock could rally strongly2025 Major Catalysts & Breakout Confirmation Trade Signals - Newser
How robust is Atara Biotherapeutics Inc. (AT20) stock financial positionPortfolio Growth Summary & Accurate Entry and Exit Point Alerts - Newser
Why analysts remain bullish on Atara Biotherapeutics Inc. stockTrade Analysis Report & Expert Curated Trade Setup Alerts - Newser
Can Atara Biotherapeutics Inc. (AT20) stock sustain revenue momentum2025 Trading Recap & Free Long-Term Investment Growth Plans - Newser
Is Atara Biotherapeutics Inc. stock attractive for long term wealth buildingQuarterly Risk Review & Expert Verified Movement Alerts - Newser
Will Atara Biotherapeutics Inc. (AT20) stock benefit from infrastructure billJuly 2025 PostEarnings & Verified Short-Term Plans - Newser
Atara Biotherapeutics: An Empty Pipeline With Little Gas (NASDAQ:ATRA) - Seeking Alpha
Pierre Fabre Pharmaceuticals Announces Transfer from Atara Biotherapeutics of the Biologics License Application (BLA) for Tabelecleucel as Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) (PR Newswire) - Aktiellt
0.80%
4.56%
자본화:
|
볼륨(24시간):